News brief.
State legislators opened their 2001 sessions tired of waiting for Congress to add a drug benefit to Medicare and determined to act on their own to make it easier for seniorsand, in many cases, others without health insurance drug coverageto afford the prescriptions they need. According to the National Conference of State Legislators, bills were introduced in 44 states to use bulk purchasing clout to get lower drug prices for their residents, force manu-facturers to give discounts to a wider group of buyers, subsidize drug purchases for those in a budget squeeze or otherwise address the problem of drug costs zooming beyond the means of many. But by mid-spring, it was evident that Congress is not alone in its inability to resolve the drug problem; very few state initiatives are going to become law.
In Washington State, drug-makers defeated a bill to establish a state-wide formularyand have manufacturers bid competitively for places on the list. Moreover, the legislature's budget panel killed a measure that would have sub-sidized drug purchases for the poor and elderly at a cost of $40 million.
In Montana, a plan to let seniors use half their drug outlays as a credit against state income taxes was killed by a 43-57 vote in the House.
In Mississippi, a bill to extend Medicaid's drug benefit to seniors with incomes below 250 percent of the federal poverty level died in a House committee.
In South Dakota, separate bills demanding that drugmakers offer all buyers the discounts offered to some were killed in Senate and House committees.
The Wyoming legislature adjourned without acting on a measure to have a state agency set maximum prices for prescription drugs.
A budget squeeze in Kansas had officials considering cutting back or delaying implementation of a drug-buying assistance program passed by the legislature last year and due to begin July 1.
Even bills that passed the legislatures ran into political problems. For instance, a Virginia proposal to spend $145,000 to promote pharmaceutical companies' existing programs to provide free drugs to indigents was sent back to the lawmakers by the governor, who wanted language added to clarify that the measure would go into effect only after special funding was appropriated.
As the difficulties of passing state-specific laws became clearer, the states have been turning to alternative approaches. The New Mexico legislature passed a resolution asking Congress to be quick about adding a prescription benefit to Medicare. Officials from New England and the mid-South states began work on forming broad drug-buying coalitions to get cheaper prices for their citizens. And a group of state attorneys general are developing a class action against drug companies to force them to change the way they calculate prices charged for Medicaid programsand to pay back years of alleged overcharges.
Daniel Moskowitz. States in Rx fix. Business and Health 2001;5:16.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More